ChengDa Pharmaceuticals Co. Ltd. - Asset Resilience Ratio
ChengDa Pharmaceuticals Co. Ltd. (301201) has an Asset Resilience Ratio of 11.71% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s Asset Resilience Ratio has changed over time. See financial flexibility index of ChengDa Pharmaceuticals Co. Ltd. to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down ChengDa Pharmaceuticals Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 301201 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥281.96 Million | 11.71% |
| Total Liquid Assets | CN¥281.96 Million | 11.71% |
Asset Resilience Insights
- Moderate Liquidity: ChengDa Pharmaceuticals Co. Ltd. has 11.71% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
ChengDa Pharmaceuticals Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare ChengDa Pharmaceuticals Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 28.06% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for ChengDa Pharmaceuticals Co. Ltd. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for ChengDa Pharmaceuticals Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 39.31% | CN¥957.65 Million ≈ $140.13 Million |
CN¥2.44 Billion ≈ $356.53 Million |
+5.85pp |
| 2022-12-31 | 33.46% | CN¥776.89 Million ≈ $113.68 Million |
CN¥2.32 Billion ≈ $339.77 Million |
-- |
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food… Read more